The first pediatric case of staphylococcus aureus with heterogenous resistant to vancomycin endocarditis in Thailand

Journal of the Medical Association of Thailand

Volumn 88, Issue SUPPL. 8, 2005, Pages

  Phongsamart, Wanatpreeya ^a   Srifeungfung, Somporn ^a   Tiensasitorn, Chuntima ^a   Vanprapar, Nirun ^a   Chearskul, Sanay ^a   Chokephaibulkit, Kulkunya ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Endocarditis; GISA; hVISA; MRSA; Staphylococcus aureus; VISA

Indexed keywords

AMIKACIN; COTRIMOXAZOLE; RIFAMPICIN; VANCOMYCIN;

ANAMNESIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERIUM MUTANT; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; CONGENITAL HEART DISEASE; FEMALE; HEART SURGERY; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INFANT; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; THAILAND;

ANTI-BACTERIAL AGENTS; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; INFANT; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THAILAND; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 31744447170     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hunstad DA, St.Geme JW. Staphylococcus aureus with reduced susceptibility to glycopeptide antibiotics. Pediatr infect Dis 2000;19:1093-5.
2. Hiramatsu K, Hanaki H, Ino T, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-46.
3. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340:493-501.
4. Rotun SS, McMath V, Schoonamker DJ, Maupin PS, Tenover FC, Hill BC, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5:147-9.
5. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin: Illinois, 1999. MMWR 2000;48: 1165-7.
6. Hiramutsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
7. Kim HB, Park WB, Lee KD, Choi YJ, Park SW, Oh MD, et al. Nationwide surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in Korea. J Clin Microbiol 2003;41:2279-81.
8. Song JH, Hiramatsu K, Suh JY, Ko KS, Ito T, Kapi M, et al; Asian Network for Surveillance of Resistant Pathogens Study Group. °Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004;48:4926-8.
9. Van Griethuysen A, Van t Veen A, Buiting A, Walsh T, Kluytmans J. High percentage of methicillinresistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J Clin Microbiol 2003;41:2487-91.
10. Cartolano GL, Cheron M, Benabid D, Leneveu M, Boisivon A. Association of Hospital Bacteriologists, Virologists and Hygiene Professionals. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 2004;10:448-51.
11. Witte W. Glycopeptide resistant Staphylococcus. J Vet Med B Infect Dis Vet Public Health 2004;51:370-3.
12. Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillinresistant Staphylococcus aureus lineages. Emerg Infect Dis 2004;10:855-7.
13. Nonhoff C, Denis O, Struelens MJ. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals. Clin Microbiol Infect 2005;11:214-20.
14. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR 2002;51:565-7.
15. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR 2002;51:902.
16. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus-New York, 2004. MMWR 2004; 53:322-3.
17. Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, Dhiraputra C, Susaemgrat W, Ito T, et al. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin. J Clin Microbiol 2001;39:591-5.
18. th ed. NCCLS approved standard M7-A6. Villanova, PA:NCCLS, 2003.
19. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mμ50. Antimicrob Agents Chemother 2000;44:2276-85.
20. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003;4:5-14.
21. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, et al. Epidemiological and micrbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility, United States, 1997-2001. Clin Infect Dis 2003;36:429-39.
22. Ariza J, Pujol M, Cabo J, Pena C, Fernandez N, Linares J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999;353:1587-8.
23. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003;47:1262-6.
24. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycinintermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-51.
25. Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by Staphylococcus aureus with inducible vancomycin heteroresistance. Clin Infect Dis 1999;29:760-7.
26. Hiramatsu K.Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1:147-55.
27. Cosgrove SE, Caroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004;39:539-45.
28. Wootton M, Howe RA, Walsh TR, Bennett PM, MacGowan AP. In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and hetero VRSA (hVRSA). J Antimicrob Chemother 2002;50:760-1.
29. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin-United Staes, 2002. MMWR 2002;51:565-7.